U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818967) titled 'A Study of Abemaciclib (LY2835219) in Healthy Participants' on Aug. 26.
Brief Summary: The main purpose of this study is to compare different forms of abemaciclib (LY2835219) to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 12 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 10 days.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: Abemaciclib Tablet (Test Formulation)
Administered orally as a tablet in one of t...